



ASX/Media Release

19 December 2016

ASX code: PIQ

Proteomics International

LABORATORIES LTD

Diabetic Kidney Disease patent granted in Russia

Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) has been granted a patent in the Russian Federation for the company's breakthrough diagnostic and prognostic test for diabetic kidney disease, "PromarkerD".

By country, the Russia Federation has the fifth largest number of adults with diabetes (16.6 million) behind China, India, USA and Brazil, resulting in an estimated USD14 billion in diabetes related health expenditure.

Russian Federation Patent number 2596486, titled "Biomarkers Associated with Pre-Diabetes, Diabetes and Diabetes Related Conditions" became effective on the 10th August 2016 and will extend until 20 September 2031.

Patent protection for the PromarkerD test has already been granted in USA, Australia, Singapore and China, with patents pending in other major global jurisdictions.

PromarkerD - a predictive and diagnostic test for diabetic kidney disease

In a four year 576 person clinical study PILL has shown PromarkerD can correctly predict 95% of the previously kidney disease-free diabetic patients who go on to develop chronic kidney disease. There is currently no available test for predicting the onset of diabetic kidney disease.

PromarkerD can also diagnose diabetic patients already suffering from chronic kidney disease that the current standard tests miss.

There are a number of potential routes to market for PromarkerD. The first licensing deal for the in-vitro diagnostic (IVD) version of the test has been signed for Central America and kit production has commenced. Separately, the Laboratory Developed Test (LDT) version of PromarkerD has shown robust performance under testing, and discussions are in progress with a number of potential certified laboratories for commercialisation of the LDT in Europe and the USA.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Greg Wood [Corporate Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories (PILL)

PILL (ASX: PIQ) is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

- 1. Diagnostics:** Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.
By 2020 the biomarkers market is estimated to double in size to \$45.6 billion, and the personalised medicine market is forecast to be worth over \$149 billion.
- 2. Analytical services:** Specialist contract research fee-for-service model – focus on biosimilars QC.
The global biosimilars market is expected to reach \$6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.
- 3. Drug discovery:** Therapeutic peptide drug discovery - focus on painkillers and antibiotics.
The global peptide therapeutics market is currently estimated to be worth \$18 billion and is expected to increase at over 10% per year during 2016-2025.

In combination these areas offer, respectively, medium term products, near term cash flow, and blue sky potential by harnessing one complementary workflow centred on proteins.